Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | TRPM8 | Q7Z2W7 | 7/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21807823 | 0.77 | TSHR (0.37) | TSHRALDH1A1TRPM8SMN1; SMN2NPC1 | |
| SCHEMBL22496056 | 0.73 | — | — | |
| SCHEMBL28508383 | 0.72 | S1PR3 (0.34) | TSHRALDH1A1SMN1; SMN2NPC1LMNA | |
| SCHEMBL22496063 | 0.66 | ALDH1A1 (0.40) | ALDH1A1TRPM8SMN1; SMN2NPC1LMNA | |
| SCHEMBL4962367 | 0.65 | RPLP1 (0.40) | TSHRALDH1A1TRPM8SMN1; SMN2LMNA | |
| SCHEMBL2369958 | 0.65 | TSHR (0.39) | TSHRALDH1A1TRPM8SMN1; SMN2MEN1 | |
| SCHEMBL22496037 | 0.64 | ALDH1A1 (0.54) | ALDH1A1 | |
| SCHEMBL28635252 | 0.63 | PTGIR (0.34) | TSHRSMN1; SMN2MAPTKMT2A | |
| SCHEMBL22496031 | 0.63 | SMN1; SMN2 (0.37) | TSHRALDH1A1SMN1; SMN2NPC1LMNA | |
| SCHEMBL21807806 | 0.62 | ALDH1A1 (0.51) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3728240-B1 | ISOXAZOLE O-LINKED CARBAMOYL CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2022-06-29 | — | — | EP | disclosed |
| US-11180488-B2 | Isoxazole o-linked carbamoyl cyclohexyl acids as LPA antagonists | BRISTOL MYERS SQUIBB CO (US) | 2021-11-23 | — | — | US | disclosed |
| EP-3728240-A1 | ISOXAZOLE O-LINKED CARBAMOYL CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2020-10-28 | — | — | EP | disclosed |
| US-20200317655-A1 | ISOXAZOLE O-LINKED CARBAMOYL CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2020-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200317655-A1 | ISOXAZOLE O-LINKED CARBAMOYL CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | LPAR3, LPAR4, LPAR6 | TSHR 412/4885ALDH1A1 3219/4885TRPM8 1098/4885 |
| US-11180488-B2 | Isoxazole o-linked carbamoyl cyclohexyl acids as LPA antagonists | LPAR3, LPAR6, LPAR4 | TSHR 441/4885ALDH1A1 3220/4885TRPM8 982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.